drugset / Trial / NCT04958538
MTX and Steroid for III-IV aGVHD Treatment
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Timeline
- Start
- 2021-04-21
- Primary completion
- 2022-12-31
- Completion
- 2023-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 5 mg | — |
| Subject | Methotrexate | Small molecule | 10 mg | — |
| Background | Methylprednisolone | Other / unclassified | 2 mg/kg | — |